Effects of bromocriptine on neuroleptic-induced amenorrhea, galactorrhea and impotence.
The effects of bromocriptine on neuroleptic-induced endocrinological disturbances (amenorrhea, galactorrhea and impotence) were investigated. Bromocriptine (5.0-7.5 mg/day) was administered to psychiatric patients receiving neuroleptics and developing hyperprolactinemia. The following results were obtained. Menses recurred in 7 of 10 patients with amenorrhea. A decrease in lactation appeared in 5 of 6 patients with galactorrhea. A significant increase in the serum levels of testosterone was observed after 8 weeks of the treatment in male patients. (N = 6). There was no remarkable deterioration in regard to the psychotic symptoms in schizophrenic patients. (N = 7). In non-schizophrenic patients (N = 9), a significant improvement was observed in regard to "somatic concern" (in Brief Psychiatric Rating Scale).
D000293:Adolescent; D000328:Adult; D000568:Amenorrhea / Q000097:blood / Q000139:chemically induced*; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001971:Bromocriptine / Q000627:therapeutic use*; D007172:Erectile Dysfunction / Q000097:blood / Q000139:chemically induced*; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D005687:Galactorrhea / Q000097:blood / Q000139:chemically induced*; D006801:Humans; D006966:Hyperprolactinemia / Q000139:chemically induced; D007775:Lactation Disorders / Q000139:chemically induced*; D007986:Luteinizing Hormone / Q000097:blood; D008297:Male; D008875:Middle Aged; D011388:Prolactin / Q000097:blood; D011618:Psychotic Disorders / Q000188:drug therapy*; D013739:Testosterone / Q000097:blood
D014150:Antipsychotic Agents; D001971:Bromocriptine; D013739:Testosterone; D011388:Prolactin; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone